Zevra Therapeutics (ZVRA) Q2 2026 earnings summary

Executive summary

• Net revenue for Q2 2026 reached $39.7 million, up 53% year-over-year, driven by strong MIPLYFFA sales and global expanded access reimbursements.

• Achieved net income of $8.8 million for Q2 2026, down from $74.7 million in Q2 2025 due to prior-year one-time gains.

• Strong cash position of $260.2 million as of June 30, 2026, supporting ongoing pipeline and global expansion.

• Intellectual property for MIPLYFFA strengthened with Orange Book listing through 2041; patent term extension pending.

• Ongoing regulatory efforts in Europe for arimoclomol, with a re-examination process underway after a negative CHMP opinion; decision expected in Q4.

Financial highlights

• Q2 2026 net revenue was $39.7 million, up $13.8 million (53%) from Q2 2025; MIPLYFFA contributed $30.2 million, OLPRUVA $0.2 million, global EAP $9.0 million, and AZSTARYS royalties $0.3 million.

• Operating expenses were $21.0 million, down from $24.2 million year-over-year; R&D expense increased to $4.5 million, SG&A decreased to $11.6 million.

• Cost of product revenue decreased to $1.5 million in Q2 2026 from $12.4 million in Q2 2025, reflecting lower inventory write-downs.

• Net income was $8.8 million ($0.14 per share); adjusted net income excluding warrant charge was $15.2 million ($0.25 per share).

• Cash equivalents and investments totaled $260.2 million as of June 30, 2026, up $23.4 million from March 31, 2026.

Outlook and guidance

• Confident in unlocking newly diagnosed NPC patients and expanding the addressable market, estimated at 350–900 U.S. patients.

• Sufficient liquidity to fund operations for at least the next twelve months and foreseeable future.

• Celiprolol phase III DISCOVER trial ongoing, with 66 patients enrolled and strategies in place to accelerate enrollment.

• Ongoing efforts to secure European approval for arimoclomol (MIPLYFFA) for NPC; re-examination decision anticipated in Q4 2026.

• Expenses expected to fluctuate due to ongoing clinical trials, regulatory activities, and potential pipeline expansion.